Abstract:Introduction: Evasion of the immune system is a hallmark of cancer and understanding immune escape mechanisms has led to the development of immunotherapies to boost anti-tumor immunity. CD47 is an immunosuppressive protein that transduces a "don't eat me" signal when bound to the SIRPα receptor on antigen presenting cells (APCs). Cancer cells exploit CD47 to block phagocytosis by APCs and dampen anti-tumor immune responses. Various inhibitors of the CD47-SIRPα signaling axis, including monoclonal antibodies, have been developed as immunotherapeutic agents for administering CD47 blockade in cancer patients, and are currently being evaluated in clinical trials. Understanding mechanisms of tumor resistance to CD47-targeted immunotherapy will guide its clinical development and could inform rational combination therapies to enhance its efficacy. Since CD47 is prognostically and functionally relevant in non-small cell lung cancer (NSCLC), we investigated the response of two syngeneic, murine lung cancer models to CD47 loss-of-function (LOF). Methods: CRISPR/Cas9 was used to knockout (KO) CD47 in two murine (LLC, CMT167) syngeneic models of NSCLC. Tumor growth studies were conducted in immune competent (C57BL/6) mice orthotopically implanted with wildtype (WT) or CD47 KO cells. Immunophenotyping of tumors was done prior to humane endpoints using flow cytometry to compare immune cell infiltration in WT versus CD47 KO tumors to assess lung tumor response to CD47 LOF. Results: Survival analyses of immunocompetent hosts with orthotopic LLC and CMT tumors revealed that mice with CD47 KO tumors lived longer than those with WT tumors, although CD47 KO tumors were ultimately lethal. Tumor immunophenotyping revealed higher frequencies of MHC-IIhighCD80+ M1 macrophages and activated cytotoxic CD69+CD8+ T cells in CD47 KO tumors compared to WT. Moreover, the percentage of PD-L1+ tumor and myeloid cells was greater in CD47 KO tumors compared to WT tumors, suggesting PD-L1 may be upregulated on various cell types in the TME as a compensation mechanism when CD47 is inhibited. Conclusion: Consistent with the literature, our findings show that CD47 LOF in lung cancer cells prolongs the survival of tumor-bearing mice and promotes infiltration of anti-tumor immune cells in two orthotopic, syngeneic NSCLC models. Upregulation of PD-L1 in cancer and myeloid cells from CD47 KO tumors was also observed, revealing a putative PD-L1-driven mechanism of resistance to CD47 blockade. Although additional preclinical and clinical studies are needed to confirm the generalizability of our observations and to validate them in patients treated with CD47-targeted therapy, our findings provide evidence to support continued development of approaches for combining CD47 and PD-L1 blockade as an effective immunotherapeutic strategy for the treatment of NSCLC. Citation Format: Asa P.Y Lau, Kelsie L Thu. Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B007.

Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer

N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β

LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape

Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer

H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer.

Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung Cancer

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8 + T-cell-dependent antitumor immunity

Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis

PLA2G2D promotes immune escape in non‐small cell lung cancer by regulating T cell immune function through PD‐L1‐expressing extracellular vesicles

Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

Preliminary Mechanisms of Regulating PD‑L1 Expression in Non‑small Cell Lung Cancer During the EMT Process.

N-terminal Acetylation of Transcription Factor LIP Induces Immune Therapy Resistance Via Suppression of PD-L1 Expression in Non-Small Cell Lung Cancer

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

KLF12 Transcriptionally Regulates PD‐L1 Expression in Non‐small Cell Lung Cancer

KRAS Mutants to Regulate PD-L1 Expression Through NF-ƘB and HIF-1α Pathways in Non-Small Cell Lung Cancer Cells.

Hypoxia‐inducible Factor‐1α and Nuclear Factor‐κb Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non‐small‐cell Lung Cancer Cells